TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30026567

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26297325

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g kg(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Calcium carbonate (0.2 g kg(‐1))
Number of subjects: 11
Study: 25271389

Group type: EXPERIMENTAL
Intervention: Parenteral nutritional support
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Enteral nutritional support
Number of subjects: 2400
Study: 22002790

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) protocol with reward (tone of 1000 Hz) when theta AP was reduced
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment (random administration of the same tone)
Number of subjects: 14
Study: 20080034

Group type: EXPERIMENTAL
Intervention: High-dose (HD) group: loading dose of selenium as selenite 15.18 micromol over 2 h and thereafter 10.12 micromol/d as a continuous intravenous infusion (CIV) for 10 d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Very-high-dose (VHD) group: loading dose of 25.30 micromol over 2 h and thereafter 20.24 micromol as a CIV for 10 d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (HD and VHD)
Number of subjects: 20
Study: 18645551

Group type: EXPERIMENTAL
Intervention: Prosthetic hernia repair (gold standard)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 16126048

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Bifidobacteria infantis, Streptococcus thermophilus, and Bifidobacteria bifidus; Solgar, Israel) 10(9) CFU/day
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (no feed supplements)
Number of subjects: 145
Study: 12385860

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) for 28 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) for 14 days and dydrogesterone (10 mg) for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 16
Study: 12219057

Group type: EXPERIMENTAL
Intervention: Minimal ventilation (PCO(2) target >52 mm Hg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Routine ventilation (PCO(2) target <48 mm Hg)
Number of subjects: 220
Study: 18370539

Group type: EXPERIMENTAL
Intervention: Imiquimod 1% cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8077707

Group type: EXPERIMENTAL
Intervention: HBV vaccine containing 10 micrograms of S
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: PreS2 + S vaccines (2 + 10 micrograms, 4 + 20 micrograms, or 8 + 40 micrograms)
Number of subjects: 282
Study: 2809024

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with MC extract
Number of subjects: 51
Study: 736777

Group type: EXPERIMENTAL
Intervention: Short hepatic inflow occlusion (7 +/- 2 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complete hepatic vascular exclusion with prolonged warm liver ischemia (38 +/- 5 minutes)
Number of subjects: 20
Study: 30327875

Group type: EXPERIMENTAL
Intervention: Eradication therapy for H. pylori-positive gastric low-grade MALT lymphoma
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Radiation therapy with 25.2 Gy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Radiation therapy with 36 Gy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Presence of t(11,18) translocation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Monoclonality of the tumour cells
Number of subjects: 102
Study: 27978771

Group type: EXPERIMENTAL
Intervention: Buprenorphine plus medical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific behavioral interventions (primarily contingency management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-quality medical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped-care model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention strategies in buprenorphine treatment
Number of subjects: 0
Study: 26037484

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 23320608

Group type: EXPERIMENTAL
Intervention: C1-2 rotatory HVLA thrust manipulation targeting the right C1-2 articulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: C1-2 rotatory HVLA thrust manipulation targeting the left C1-2 articulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: C1-2 rotatory HVLA thrust manipulation (both right and left)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: C1-2 rotatory HVLA thrust manipulation
Number of subjects: 19
Study: 21916277

Group type: EXPERIMENTAL
Intervention: Depilatory compositions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual razor
Number of subjects: 100
Study: 19384101

Group type: EXPERIMENTAL
Intervention: Brief individual counseling session integrating motivational interviewing and principles of behavior change
Number of subjects: 409
Study: 16881773

Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 241

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 241
Study: 15743000

Group type: EXPERIMENTAL
Intervention: Probiotics (fermented milk product Cultura containing live lactobacilli (La-5) and bifidobacteria (Bb-12), 500 ml daily for 4 weeks)
Number of subjects: 51
Study: 11549407

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9040746

Group type: EXPERIMENTAL
Intervention: Intradermal injection of recombinant human NGF (1 or 3 micrograms)
Number of subjects: 16
Study: 7684155

Group type: EXPERIMENTAL
Intervention: Continuous transurethral resection technique
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intermittent transurethral resection technique
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Trocar use
Number of subjects: 123

Group type: COMPARATOR
Intervention: High irrigating fluid pressure head (80 cm)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Low irrigating fluid pressure head (65 cm)
Number of subjects: 123
Study: 3323983

Group type: EXPERIMENTAL
Intervention: Linear-incision Nd:YAG laser iridotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Linear-incision argon laser iridotomy
Number of subjects: 30
Study: 30245328

Group type: EXPERIMENTAL
Intervention: 250 mg prednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30672232

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at Zusanli (ST 36), Neiguan (PC 6), and Hegu (LI 4) at 2 Hz, within 2 mA, on the day of operation and within 3 days after surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received the same interventions as the observation group, except opening the current source.
Number of subjects: 60
Study: 26740528

Group type: EXPERIMENTAL
Intervention: Bicycle helmet (used as an eye tracker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseball cap (used as an eye tracker)
Number of subjects: 0
Study: 24646403

Group type: EXPERIMENTAL
Intervention: Real WBV at 30 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real WBV at 50 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham WBV
Number of subjects: 0
Study: 21384133

Group type: EXPERIMENTAL
Intervention: Irbesartan 300, 600, and 900 mg o.d. for 2 months each
Number of subjects: 52
Study: 21386207

Group type: EXPERIMENTAL
Intervention: mouthrinse I (250 ppm F(‐) from amine fluoride/stannous fluoride (ASF), 0.2% zinc lactate)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: mouthrinse II (0.05% CHX, 0.05% cetylpyridinium chloride, 0.14% zinc lactate)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: mouthrinse III (0.12% CHX)
Number of subjects: 174

Group type: COMPARATOR
Intervention: tap water (negative control)
Number of subjects: 174
Study: 17627404

Group type: EXPERIMENTAL
Intervention: Milk supplement (two sachets of milk powder containing 1000 mg calcium and 80 microg vitamin K(1)) for 24 months
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 441
Study: 16135347

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FEM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of continuous femoral and sciatic nerve block (FEM/SCI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (PSOAS)
Number of subjects: 90
Study: 14535870

Group type: EXPERIMENTAL
Intervention: Propranolol (oral, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lanreotide SR (intramuscular, 30 mg once weekly, n=12)
Number of subjects: 24
Study: 11152019

Group type: EXPERIMENTAL
Intervention: Triple therapy with delavirdine, zidovudine and lamivudine, didanosine or zalcitabine for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy with delavirdine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual NRTI therapy (delavirdine plus zidovudine or 2 NRTIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delavirdine as a component of protease inhibitor‐containing regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delavirdine-containing combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delavirdine-containing treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delavirdine as a first‐line therapy with 2 NRTIs
Number of subjects: 0
Study: 8967600

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at concentrations of 0, 20, 40, 60, and 75 vol.%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of nitrous oxide and enflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane at a constant median EEG frequency of 2-3 Hz
Number of subjects: 30
Study: 1505560

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 61

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 61
Study: 6496044

Group type: EXPERIMENTAL
Intervention: Double-freeze technique
Number of subjects: 142

Group type: COMPARATOR
Intervention: Single-freeze technique
Number of subjects: 142
Study: 2426934

Group type: EXPERIMENTAL
Intervention: Intravenous heparin (5000 IU bolus followed by 830 IU/hr for 2 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 IU bolus)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No anticoagulant treatment
Number of subjects: 42
Study: 30439312

Group type: EXPERIMENTAL
Intervention: CPAP+PPS
Number of subjects: 87

Group type: COMPARATOR
Intervention: CPAP+ASB
Number of subjects: 87
Study: 25143068

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus HS111, Lactobacillus acidophillus HS101, Bifidobacterium bifidum)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 23371807

Group type: EXPERIMENTAL
Intervention: Participants anticipated a congruency-level repetition in Stroop tasks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants anticipated alternation predictions in Stroop tasks.
Number of subjects: 0
Study: 20628395

Group type: EXPERIMENTAL
Intervention: Communication skills training program (40 hours)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 98
Study: 18209633

Group type: EXPERIMENTAL
Intervention: Gently reconstituted botulinum toxin type A
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vigorously reconstituted botulinum toxin type A
Number of subjects: 7
Study: 17227525

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.5 mg IV
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 11
Study: 12374900

Group type: EXPERIMENTAL
Intervention: Imidapril (5 to 10 mg per day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Captopril (25 to 50 mg twice per day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (placebo during washout)
Number of subjects: 59
Study: 9825268

Group type: EXPERIMENTAL
Intervention: Furosemide infusion (2 x 40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide bolus injection (2 x 40 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Furosemide infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide bolus injection
Number of subjects: 20
Study: 8120709

Group type: EXPERIMENTAL
Intervention: Fish oil (8 gm daily, containing 3.2 gm eicosapentaenoic acid and 2.2 gm docosahexaenoic acid)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 25

Group type: COMPARATOR
Intervention: Olive oil ethyl esters
Number of subjects: 25
Study: 2680273

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study: 990700

Group type: EXPERIMENTAL
Intervention: Elemental diet as preoperative bowel preparation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Routine bowel preparation
Number of subjects: 26
Study: 29544154

Group type: EXPERIMENTAL
Intervention: Light fingertip touch (LT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No fingertip touch (NT)
Number of subjects: 22
Study: 27216137

Group type: EXPERIMENTAL
Intervention: FS MDPI 100/6.25 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: FS MDPI 100/12.5 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: FS MDPI 100/25 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: FS MDPI 100/50 μg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fp MDPI 100 μg
Number of subjects: 72

Group type: COMPARATOR
Intervention: FS DPI 100/50 μg
Number of subjects: 72
Study: 24824660

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS) administered at a dosage of 50 mg either once weekly or daily for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail, but implied to be a placebo or no treatment).
Number of subjects: 0
Study: 22591949

Group type: EXPERIMENTAL
Intervention: Internet-based, tailored intervention based on the Transtheoretical Model of Behavior Change (3 thirty-minute sessions over three months)
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 1590
Study: 19962418

Group type: EXPERIMENTAL
Intervention: UK beverages (apple juice, orange juice, Diet Pepsi, Sprite Zero)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK beverages (apple juice, orange juice, orange soda, diet orange soda, Sprite)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK beverages (Sunny D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK beverages (apple juice, orange juice, Coke, Diet Coke, Sprite, Sprite Zero)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK beverages (orange soda, diet orange soda, Pepsi, Diet Pepsi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK beverages (apple juice, orange juice, Diet Coke, Sprite, Sprite Zero)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesion depths
Number of subjects: 0
Study: 18678823

Group type: EXPERIMENTAL
Intervention: DHEA 100 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DHEA 400 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15837244

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 450

Group type: COMPARATOR
Intervention: Bare-metal stent (control)
Number of subjects: 450
Study: 15650536

Group type: EXPERIMENTAL
Intervention: VHS/768 kbps
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VHS/128 kbps
Number of subjects: 60

Group type: COMPARATOR
Intervention: Betacam/768 kbps
Number of subjects: 60

Group type: COMPARATOR
Intervention: Betacam/128 kbps
Number of subjects: 60
Study: 10084491

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Positional treatment
Number of subjects: 13
Study: 7578378

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEpo)
Number of subjects: 0
Study: 2299309

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide‐triamterene
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 106
Study: 525733

Group type: EXPERIMENTAL
Intervention: Domperidone given prophylactically with morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone given prophylactically with pethidine
Number of subjects: 0
Study: 31132893

Group type: EXPERIMENTAL
Intervention: Neurofeedback combined with trauma counseling (NFT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Trauma counseling alone (TC)
Number of subjects: 13
Study: 29331037

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 335

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 335
Study: 27423912

Group type: EXPERIMENTAL
Intervention: Right-hand strength training (RHT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Left-hand strength training (LHT)
Number of subjects: 23
Study: 24480909

Group type: EXPERIMENTAL
Intervention: Cluster 1 - Elderly patients adapted to pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster 4 - Younger patients with acute pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster 2 - Patients with chronic severe pain with comorbid depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster 3 - Younger patients with subacute pain and emotional distress
Number of subjects: 0
Study: 22592139

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30
Study: 19220378

Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin
Number of subjects: 2196

Group type: COMPARATOR
Intervention: FU plus oxaliplatin
Number of subjects: 2196
Study: 17916952

Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc-enriched yeast
Number of subjects: 0
Study: 16154018

Group type: EXPERIMENTAL
Intervention: Interventional strategy (routine angiography followed by revascularisation)
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Conservative strategy (ischaemia-driven or symptom-driven angiography)
Number of subjects: 1810
Study: 11881907

Group type: EXPERIMENTAL
Intervention: Tapping to click trains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapping to continuous FM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapping to continuous FM with varied depth
Number of subjects: 0
Study: 9892450

Group type: COMPARATOR
Intervention: Usual dissemination of practice recommendations (n = 14)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active dissemination (n = 13)
Number of subjects: 27
Study: 8952838

Group type: EXPERIMENTAL
Intervention: Isoproterenol test (sensitised protocol)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Passive test (non-sensitised protocol)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both tests (passive and isoproterenol)
Number of subjects: 108
Study: 1915517

Group type: EXPERIMENTAL
Intervention: High dose salicylate (100 mg/kg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low dose salicylate (30 mg/kg per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 7006132

Group type: EXPERIMENTAL
Intervention: 3.5% amino acids plus 10% fat
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3.5% amino acids plus 2.5% glucose
Number of subjects: 12
Study: 31085686

Group type: EXPERIMENTAL
Intervention: Contemporary instruction (CI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Traditional instruction with video (TIV)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Traditional instruction with no video (TI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 96
Study: 29027116

Group type: EXPERIMENTAL
Intervention: Intracoronary and intravenous melatonin (total 50 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26786929

Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA) use at start of chemoradiotherapy
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA) use both at start of and still after chemoradiotherapy
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) use
Number of subjects: 1869
Study: 23928707

Group type: EXPERIMENTAL
Intervention: High concentration group (ropivacaine 0.2% infusion)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low concentration group (ropivacaine 0.1% infusion)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo infusion group (saline 0.9% infusion)
Number of subjects: 99
Study: 22873651

Group type: EXPERIMENTAL
Intervention: Physical exercise (protocols performed three times a week for 10 weeks, 30 sessions in total)
Number of subjects: 0
Study: 21305734

Group type: EXPERIMENTAL
Intervention: PreOp group (carbohydrate drink 200 mL two hours before surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (fasted overnight)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PreOp group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 17388091

Group type: EXPERIMENTAL
Intervention: Aerobic exercise 2 times per week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic exercise 3 times per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50